Tadalafil Tablet, Coated
Product Images NDC 46708-178

Each tablet contains 10mg of Tadalfil USP. Usual dosage should be seen in the accompanying Heratue for dosage. Store at 25°C (17°F); excursions permissible 1015° 10 30°C (80° b 86°F) [see USP controlled room temperature]. Warning: Keep out of reach of children. Manufacturer: Alembic Pharmaceuticals Limited (Formulation Division), Village Panelay P. O. Tapura, Near Basia, Taluke-Helol, Panchmaha 389360, Gujarat India. NDC 46708-179-30 Tadalafil Tablets, USP. Tablets should not be it - Entire dose should be taken. Rx only 30 Tablets. Lot EXP.*

Each coated tablet of Tadalafil USP contains 20mg of the drug. The recommended dosage can be found in the accompanying literature. Store at room temperature and away from children. The manufacturer is Alembic Pharmaceuticals Limited, located in Gujarat, India. These tablets are only available by prescription and should be taken whole. The prescription comes with 30 tablets and should be dispensed in a proper container. The Lot and expiration date is also provided.*

The text describes a figure showing the mean changes in IPSS Total Score in BPH patients by visit in a study involving Tadalafil Tablet 5mg and Placebo. The changes were measured over a treatment duration of 12 weeks.*

This is a description for Tadalafil Tablets, USP. Each coated tablet contains 5mg of Tadalafil USP. The usual dosage information can be found in the accompanying literature. The tablets should be stored at a controlled room temperature of 25°C (77°F), with permitted excursions between 10-30°C (80-86°F), as per USP guidelines. A warning to keep the tablets out of reach of children is mentioned. The tablets are manufactured by Alembic Pharmaceuticals Limited (Formulation Division) in Gujarat, India. The NDC number is 46708-178-30. The tablets should not be split, and the entire dose should be taken. The packaging includes 30 tablets and should be kept in a tight container. Lot number listed is B0 with the Mig L No. G989.*

This appears to be a graph showing the change from baseline in IPSS (International Prostate Symptom Score) total score in patients with benign prostatic hyperplasia (BPH) treated with tadalafil tablets at a dose of 5 mg. The x-axis shows the duration of treatment in weeks and the y-axis shows the mean IPSS changes at each visit. However, without the actual image of the graph, we cannot provide a more accurate description.*

The text shows a chart or graph labeled "Figure 7" that displays the mean total IPSS changes by visit in BPH patients who took Tadalafil tablet for once daily use with Finasteride. The chart has four columns labeled "Weeks of Therapy" with numbers 0, 4, 12, and 26. Additionally, the chart has two rows with labels "Tadalfil/Finasteride" and "Placebo/Finasteride." The chart also shows a LS Mean Change from Baseline denoted by the number 1 with some statistical figures, including the number 0.001 and the letter 'b' with "<0.05." The did not provide clear descriptions of the chart or figures, making it difficult to interpret the data.*

The text describes a graph showing the mean IPSS changes in ED/BPH patients by visit in Study L, comparing the effects of Tadalafil Tablet 5 mg and a placebo, over a duration of treatment in weeks. The graph shows that there was a significant decrease in IPSS total scores with Tadalafil compared to placebo.*

This is a graph showing the plasma concentration of Tadalafil in micrograms per liter over time in hours. It compares the effect of a single 20 mg dose and a single 5 mg dose of Tadalafil, as well as once-daily 5 mg Tadalafil following five consecutive days of administration.*